Last reviewed: June 2020
Last updated: November  2019

Summary

Definition

History and exam

Key diagnostic factors

  • recent chemotherapy
  • fever
  • tachycardia
  • hypotension

Other diagnostic factors

  • age >65 years
  • prior episodes of neutropenia following chemotherapy
  • Eastern Cooperative Oncology Group performance status (ECOG PS) ≥1
  • haematological malignancies
  • prior antibiotic regimens
  • albumin <35 g/L (<3.5 g/dL)
  • pretreatment haemoglobin <120g/L (<12 g/dL)
  • low first-cycle nadir absolute neutrophil count (<500 cells/microlitre)
  • abnormal breath sounds or cough
  • shortness of breath
  • abdominal pain
  • nausea or vomiting
  • diarrhoea
  • dysuria and pyuria
  • skin erythema, warmth, tenderness
  • mucositis or oral ulcers
  • infection, inflammation, or ulceration of genital and anal area
  • infected indwelling catheters
  • concurrent radiotherapy
  • exposures to infections
  • sinus tenderness

Risk factors

  • age >65 years
  • albumin <35 g/L (<3.5 g/dL)
  • pre-existing organ dysfunction (heart, liver, kidney disease)
  • pre-treatment haemoglobin <120 g/L (<12 g/dL)
  • full-dose intensity chemotherapy
  • low first-cycle nadir absolute neutrophil count (<500 cells/microlitre)
  • haematological malignancies
  • concurrent radiotherapy
  • prior episodes of neutropenia following chemotherapy
  • female sex
  • Eastern Cooperative Oncology Group performance status (ECOG PS) >1
  • advanced-stage disease
  • prior chemotherapy
  • corticosteroids

Diagnostic investigations

1st investigations to order

  • FBC and differential
  • urea and creatinine
  • liver function tests (LFTs)
  • blood cultures for bacteria: peripheral and central venous catheters
  • chest x-ray
More 1st investigations to order

Investigations to consider

  • stool culture
  • urine culture
  • lumbar puncture
  • fungal cultures and serologies (beta-glucan and galactomannan)
  • viral molecular assay
  • echocardiogram
  • CT scans of the chest, abdomen, and pelvis
More investigations to consider

Treatment algorithm

Contributors

Internist and Professor of Medicine

Department of Infectious Diseases, Infection Control and Employee Health

Division of Internal Medicine

The University of Texas M.D. Anderson Cancer Center

Houston

TX

Disclosures

KVIR has research grants from Merck, Inc., Shionogi, and JMI Laboratories for the performance of in-vitro studies of novel antimicrobial agents.

Specialist in Infectious Disease & Internal Medicine

Infectious Disease Institute, Soroka Medical Center

Senior Lecturer, Faculty of Health Sciences

Ben-Gurion University of the Negev

Beer Sheba

Israel

Disclosures

LN has given two educational lectures sponsored by MSD.

Dr Kenneth Rolston and Dr Lior Nesher would like to gratefully acknowledge Dr Caron Jacobson and Dr Joseph Antin, previous contributors to this topic.

Peer reviewersVIEW ALL

Price Eminent Scholar and Professor of Medicine

Director

Bone Marrow Transplant Program

Division of Hematology/Oncology

University of Florida College of Medicine

Gainesville

FL

Disclosures

JW has been reimbursed by Pfizer, Merck, Astellas, and Enzon for speaking fees, fees for educational programs, and consulting.

Director

Alfa Institute of Biomedical Sciences

Marousi

Athens

Greece

Disclosures

MF declares that he has no competing interests.

Senior Lecturer in Haematology

Honorary Consultant in Medical Oncology

St George's University of London

London

UK

Disclosures

RP has received speaker fees and been reimbursed by Roche, Amgen, Chigai, and Bayer for attending several conferences. RP is a co-author of the EORTC guidelines referenced in this topic.

Use of this content is subject to our disclaimer